Reports - Migraine Drugs Market
HealthcareMigraine Drugs Market
Migraine Drugs Market Size & Share | Growth Analysis 2035 by Treatment (Acute, Preventive) by Therapeutic class (CGRP Monoclonal Antibodies, CGRP Small Molecule Antagonists, Acetylcholine inhibitors/ neurotoxins, Triptans, Ditans, Ergot alkaloids, NSAIDs) by Route of Administration (Oral, Injectable, Others) by Age group (Pediatric, Adult, Geriatric) by Availability (prescription drugs, Over-the-Counter (OTC) drugs) by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Industry Leaders Trust Us For Actionable Intelligence
Table of Contents
Chapter 1 Executive Dashboard
1. Strategic Imperatives
Chapter 2 Premium Insights
1. Top 3 Trends to Watch
2. Demand and Supply Trends
3. Top 3 Strategies Followed by Major Players
4. Top 3 Predictions by Vantage Market Research
5. Top Investment Pockets
6. Insights from Primary Respondents
Chapter 3 Global Migraine Drugs Market - Segment Analysis
1. Overview
2. Global Migraine Drugs Market, 2021 - 2035 (USD Million)
3. Global Migraine Drugs Market - by Treatment
3.1. By Acute
3.2. By Preventive
4. Global Migraine Drugs Market - by Therapeutic class
4.1. By CGRP Monoclonal Antibodies
4.2. By CGRP Small Molecule Antagonists
4.3. By Acetylcholine inhibitors/ neurotoxins
4.4. By Triptans
4.5. By Ditans
4.6. By Ergot alkaloids
4.7. By NSAIDs
5. Global Migraine Drugs Market - by Route of Administration
5.1. By Oral
5.2. By Injectable
5.3. By Others
6. Global Migraine Drugs Market - by Age group
6.1. By Pediatric
6.2. By Adult
6.3. By Geriatric
7. Global Migraine Drugs Market - by Availability
7.1. By prescription drugs
7.2. By Over-the-Counter (OTC) drugs
8. Global Migraine Drugs Market - by region
8.1. North America
8.2. Europe
8.3. Asia Pacific
8.4. Latin America
8.5. Middle East & Africa
9. Market comparative analysis
Chapter 4 North America Migraine Drugs Market - Segment Analysis
1. Overview
2. North America Migraine Drugs Market, 2021 - 2035 (USD Million)
3. North America Migraine Drugs Market - by Treatment
3.1. By Acute
3.2. By Preventive
4. North America Migraine Drugs Market - by Therapeutic class
4.1. By CGRP Monoclonal Antibodies
4.2. By CGRP Small Molecule Antagonists
4.3. By Acetylcholine inhibitors/ neurotoxins
4.4. By Triptans
4.5. By Ditans
4.6. By Ergot alkaloids
4.7. By NSAIDs
5. North America Migraine Drugs Market - by Route of Administration
5.1. By Oral
5.2. By Injectable
5.3. By Others
6. North America Migraine Drugs Market - by Age group
6.1. By Pediatric
6.2. By Adult
6.3. By Geriatric
7. North America Migraine Drugs Market - by Availability
7.1. By prescription drugs
7.2. By Over-the-Counter (OTC) drugs
Chapter 5 Europe Migraine Drugs Market - Segment Analysis
1. Overview
2. Europe Migraine Drugs Market, 2021 - 2035 (USD Million)
3. Europe Migraine Drugs Market - by Treatment
3.1. By Acute
3.2. By Preventive
4. Europe Migraine Drugs Market - by Therapeutic class
4.1. By CGRP Monoclonal Antibodies
4.2. By CGRP Small Molecule Antagonists
4.3. By Acetylcholine inhibitors/ neurotoxins
4.4. By Triptans
4.5. By Ditans
4.6. By Ergot alkaloids
4.7. By NSAIDs
5. Europe Migraine Drugs Market - by Route of Administration
5.1. By Oral
5.2. By Injectable
5.3. By Others
6. Europe Migraine Drugs Market - by Age group
6.1. By Pediatric
6.2. By Adult
6.3. By Geriatric
7. Europe Migraine Drugs Market - by Availability
7.1. By prescription drugs
7.2. By Over-the-Counter (OTC) drugs
Chapter 6 Asia Pacific Migraine Drugs Market - Segment Analysis
1. Overview
2. Asia Pacific Migraine Drugs Market, 2021 - 2035 (USD Million)
3. Asia Pacific Migraine Drugs Market - by Treatment
3.1. By Acute
3.2. By Preventive
4. Asia Pacific Migraine Drugs Market - by Therapeutic class
4.1. By CGRP Monoclonal Antibodies
4.2. By CGRP Small Molecule Antagonists
4.3. By Acetylcholine inhibitors/ neurotoxins
4.4. By Triptans
4.5. By Ditans
4.6. By Ergot alkaloids
4.7. By NSAIDs
5. Asia Pacific Migraine Drugs Market - by Route of Administration
5.1. By Oral
5.2. By Injectable
5.3. By Others
6. Asia Pacific Migraine Drugs Market - by Age group
6.1. By Pediatric
6.2. By Adult
6.3. By Geriatric
7. Asia Pacific Migraine Drugs Market - by Availability
7.1. By prescription drugs
7.2. By Over-the-Counter (OTC) drugs
Chapter 7 Latin America Migraine Drugs Market - Segment Analysis
1. Overview
2. Latin America Migraine Drugs Market, 2021 - 2035 (USD Million)
3. Latin America Migraine Drugs Market - by Treatment
3.1. By Acute
3.2. By Preventive
4. Latin America Migraine Drugs Market - by Therapeutic class
4.1. By CGRP Monoclonal Antibodies
4.2. By CGRP Small Molecule Antagonists
4.3. By Acetylcholine inhibitors/ neurotoxins
4.4. By Triptans
4.5. By Ditans
4.6. By Ergot alkaloids
4.7. By NSAIDs
5. Latin America Migraine Drugs Market - by Route of Administration
5.1. By Oral
5.2. By Injectable
5.3. By Others
6. Latin America Migraine Drugs Market - by Age group
6.1. By Pediatric
6.2. By Adult
6.3. By Geriatric
7. Latin America Migraine Drugs Market - by Availability
7.1. By prescription drugs
7.2. By Over-the-Counter (OTC) drugs
Chapter 8 Middle East & Africa Migraine Drugs Market - Segment Analysis
1. Overview
2. Middle East & Africa Migraine Drugs Market, 2021 - 2035 (USD Million)
3. Middle East & Africa Migraine Drugs Market - by Treatment
3.1. By Acute
3.2. By Preventive
4. Middle East & Africa Migraine Drugs Market - by Therapeutic class
4.1. By CGRP Monoclonal Antibodies
4.2. By CGRP Small Molecule Antagonists
4.3. By Acetylcholine inhibitors/ neurotoxins
4.4. By Triptans
4.5. By Ditans
4.6. By Ergot alkaloids
4.7. By NSAIDs
5. Middle East & Africa Migraine Drugs Market - by Route of Administration
5.1. By Oral
5.2. By Injectable
5.3. By Others
6. Middle East & Africa Migraine Drugs Market - by Age group
6.1. By Pediatric
6.2. By Adult
6.3. By Geriatric
7. Middle East & Africa Migraine Drugs Market - by Availability
7.1. By prescription drugs
7.2. By Over-the-Counter (OTC) drugs
Chapter 9 Key Market Dynamics
1. Introduction
2. Market Drivers
3. Market Restraints
4. Market Opportunities
5. Porter's Five Forces Analysis
6. PEST Analysis
7. Regulatory Landscape
8. Technology Landscape
9. Regional Market Trends
Chapter 10 COVID 19 Impact Analysis
1. Key strategies undertaken by companies to tackle COVID-19
2. Short term dynamics
3. Long term dynamics
Chapter 11 Marketing Strategy Analysis
1. Marketing Channel
2. Direct Marketing
3. Indirect Marketing
4. Marketing Channel Development Trends
Chapter 12 Competitive Landscape
1. Competition Matrix - 2021
2. Company Market Share Analysis - 2021
3. Key Company Activities, 2018 - 2021
4. Strategic Developments - Heat Map Analysis
5. Company Offering Evaluation
6. Company Regional Presence Evaluation
Chapter 13 Company Profiles
1. AbbVie Inc.
2. Amgen Inc.
3. Teva Pharmaceutical Industries Ltd.
4. GSK plc
5. Eli Lilly and Company
6. Pfizer Inc.
7. Bausch Health Companies Inc.
8. Gensco Pharma
9. Impel Pharmaceuticals Inc.
10. Tonix Medicines Inc.
11. Currax Pharmaceuticals LLC.
12. Lundbeck
Chapter 14 Key Primary Respondents - VERBATIM
Chapter 15 Discussion Guide
Chapter 16 Customization Offered
Chapter 17 Annexure
Chapter 18 List of Figures
Chapter 19 List of Tables
Chapter 20 List of Abbreviations
FAQ‘s
Related Reports
Contact
Toll Free Number+1 (877) 462-2282
© 2025 Vantage Market Research. All right reserved
Secured By